Domestic formulation to sustain 12%+ growth
Management expects to maintain historical domestic growth trajectory of ~12% driven by volume and new launches.
RPGLIFESCIENCES / guidance tracker
Keep management guidance in view.
RPG Life Sciences · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
growth
API business to be a growth driver with 13-molecule pipeline
API growth expected to sustain at 9-10% with a strong pipeline of 13 products and expansion into new markets.
International formulation to return to growth
Post inventory normalization, international business expected to revert to historical 9-15% growth trajectory.
CDMO projects to commercialize in FY27
Three of five CDMO projects expected to start generating revenue in FY27, two in FY28.